PGR and breast cancer: BC, being a heterogeneous pathology, can be classified through the status determination of the following receptors, Estrogen Receptor alpha (ERα), Progesterone Receptor (PR) and epidermal growth factor receptor 2 (HER2/neu), because they represent known targets for BC treatment.